Emir Hadzijusufovic

Emir Hadzijusufovic

UNVERIFIED PROFILE

Are you Emir Hadzijusufovic?   Register this Author

Register author
Emir Hadzijusufovic

Emir Hadzijusufovic

Publications by authors named "Emir Hadzijusufovic"

Are you Emir Hadzijusufovic?   Register this Author

32Publications

2249Reads

44Profile Views

Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.

Vet Comp Oncol 2019 Dec 13;17(4):553-561. Epub 2019 Aug 13.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vco.12520DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900099PMC
December 2019

A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1 in Ph+ CML.

Leuk Res 2019 03 28;78:36-44. Epub 2018 Dec 28.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Austria. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.12.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6834439PMC
March 2019

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

Vet Comp Oncol 2018 Mar 11;16(1):55-68. Epub 2017 Apr 11.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/vco.12311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824979PMC
March 2018

Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph chronic myeloid leukemia.

Exp Hematol 2018 01 12;57:50-59.e6. Epub 2017 Oct 12.

Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria; Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2017.09.012DOI Listing
January 2018

Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Leuk Res 2017 08 12;59:47-54. Epub 2017 May 12.

Medical Clinic III for Oncology, Haematology, Immunology and Rheumatology, University Hospital Bonn (UKB), Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2017.05.008DOI Listing
August 2017

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

Blood 2015 Feb 18;125(6):901-6. Epub 2014 Dec 18.

Medical Clinic for Hematology and Oncology, Campus Virchow, Charité, Medical University of Berlin, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-09-594432DOI Listing
February 2015

Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.

PLoS One 2014 29;9(1):e84417. Epub 2014 Jan 29.

Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria ; Division of Hematology & Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0084417PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906015PMC
September 2014

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.

Blood 2014 Jul 27;124(1):111-20. Epub 2014 Mar 27.

Laboratoire de Biologie et Pharmacologie Appliquée, Centre Nationale de la Recherche, Unité Mixte de Recherche 8113, Ecole Normale Supérieure de Cachan, Cachan, France; Laboratoire Central d'Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2013-10-534685DOI Listing
July 2014

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.

Haematologica 2013 Sep 28;98(9):1450-7. Epub 2013 Mar 28.

Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2012.079202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762103PMC
September 2013

Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).

Am J Blood Res 2013 5;3(2):174-80. Epub 2013 May 5.

Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna Austria ; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna Austria.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649810PMC
May 2013

H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.

Exp Hematol 2010 Oct 1;38(10):896-907. Epub 2010 Jun 1.

Department for Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2010.05.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337971PMC
October 2010

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

Exp Hematol 2010 Sep 26;38(9):782-91. Epub 2010 May 26.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2010.05.004DOI Listing
September 2010

Chemotherapy in canine acute megakaryoblastic leukemia: a case report and review of the literature.

In Vivo 2009 Nov-Dec;23(6):911-8

Department for Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
March 2010

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Cancer Res 2010 Feb 9;70(4):1513-23. Epub 2010 Feb 9.

Department of Internal Medicine I, Division of Hematology and Hemostaseology, Institute of Immunology, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-2181DOI Listing
February 2010

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

Vet Immunol Immunopathol 2009 Dec 18;132(2-4):243-50. Epub 2009 May 18.

Department of Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vetimm.2009.05.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763335PMC
December 2009